| Home | Contact |
![]() |
![]() |
|
|
Deciphera's MET ProgramSolid tumor program DP-3590 preclinical selective cMET inhibitors multi-kinase targeted cMET inhibitors Deciphera has developed inhibitors of cMET kinase for the treatment of a variety of solid tumors. cMET kinase is overexpressed and/or activated in a widespread number of human solid tumors. Overactivity of cMET increases tumor cell proliferation, survival, motility, and invasiveness. DP-3590 is an orally active and selective cMET inhibitor which spares the kinome including nearest neighbor kinases RON and AXL. |
| Home | Senior Management | Platform | BCR-ABL | KIT | BRAF | News | Partners | Contact | |
Copyright © Deciphera Pharmaceuticals,
LLC 2002-2009 |